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CASE REPORT
SARS-CoV-2: A potential trigger of dermato-
neuro syndrome in a patient
with scleromyxedema
Mike Fritz, BS,a Daniel Tinker, MD,b Alex W. Wessel, BS,c Gabriela M. Morris, MD,b
Linda Goldenberg, MSN, RN,d Mark Fesler, MD,d Lokesh Rukmangadachar, MD, MS,e and
M. Yadira Hurley, MDb
Lexington, Kentucky and St. Louis, Missouri
Key words: COVID-19; dermato-neuro syndrome; epilepsy; IVIG; mucinoses; SARS-CoV-2; scleromyxedema.
INTRODUCTION
Scleromyxedema (SMX) is characterized by
excessive mucin deposition in connective tissues
and skin.1 It shares clinical features with other
mucinoses, including generalized myxedema, pre-
tibial myxedema, reticular erythematous mucinosis,
and scleredema.1 However, diagnosis of SMX is
distinguished by the following criteria: absence of
thyroid disease, presence of monoclonal gammop-
athy (classically IgG l), and cutaneous eruption of
waxy papules and plaques, characterized histopath-
ologically by increased dermal mucin, fibroblast
proliferation, and fibrosis.2 SMX also causes multi-
system disease with approximately 20% fatality.3
Dermato-neuro syndrome (DNS), a potentially
fatal complication of SMX, occurs in approximately
18% of the patients.4 It presents with fever and
neurologic disturbances including confusion, dysar-
thria, seizures, and coma. The pathogenesis of DNS
remains uncertain; however, reports speculate that
elevated levels of vasoactive cytokines (eg, inter-
leukin 6) during viral infection may contribute by
compromising the blood-brain-barrier.5,6 Enhanced
blood-brain-barrier permeability in the setting of
monoclonal gammopathy may elevate IgG levels in
the brain microvasculature, causing hyperviscosity,
sludging, and neurologic abnormalities.7-9 Available
literature indicates that reported cases of DNS are
frequently preceded by a flu-like prodrome3,4,9-18 or
other suspected upper respiratory tract infection.8,19
Notably, 2 case studies identified influenza A
infection in association with DNS.6,10 Here, we
describe a patient with SMX complicated by 2
episodes of DNS, each associated with different
RNA virus infections: Influenza A or SARS-CoV-2.
CASE REPORT
A 48-year-old man with a history of hypertension
initially presented with 3 months of skin tightening,
difficulty clenching his fists or opening his mouth,
and mild shortness of breath. Physical examination
revealed numerous waxy, 2 to 3-mm papules on the
upper arms, chest, post-auricular scalp, and eye-
brows. Histologic examination of lesional skin bi-
opsy material revealed increased stromal fibroblast
proliferation and mucin deposition in the upper
dermis (Fig 1), consistent with SMX. Thyroid func-
tion tests were normal, and serum protein electro-
phoresis with immunofixation revealed IgG l
paraproteinemia, leading to a diagnosis of SMX.
Initial treatment included prednisone and intrave-
nous immunoglobulin (IVIG) administered every
4 weeks at 1 g/kg of ideal body weight. Within
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patient continued IVIG maintenance therapy at
varying frequencies based on severity of cutaneous
disease.
Seven years after initial diagnosis, the patient
developed several days of flu-like symptoms
including fatigue, myalgia, sore throat, and cough.
Chest X-ray revealed a small lung infiltrate, and the
patient was treated empirically for community-
acquired pneumonia with azithromycin. Days later,
the patient presented with altered mental status,
aphasia, and tonic-clonic movements in all extrem-
ities. After hospital admission, the patient developed
fever and seizures confirmed to be status epilepticus
on electroencephalography. The patient was trans-
ferred to the intensive care unit and intubated.
Neurology consult noted left-sided motor weakness
and right-sided gaze deviation. However, computed
tomography and magnetic resonance imaging of the
head were unremarkable. Analysis of cerebrospinal
fluid (CSF) revealedmild pleocytosis (10white blood
cells/L; reference range, 0-5 cells/mL), mildly
elevated protein (47 mg/dL; reference range, 15-
45 mg/dL), and an opening pressure of 29 cm H2O.
CSF testing was negative for bacteria by culture,
herpes simplex virus 1 and 2, and varicella zoster
virus. A nasal swab polymerase chain reaction test
confirmed influenza A infection. Complete blood
count, comprehensive metabolic panel, urinalysis,
chest X-ray, and blood cultures/flow cytometry were
unremarkable. Status epilepticus was controlledwith
intravenous antiepileptics, and the patient improved
over a 3-day course of IVIG (3 g/kg of ideal body
weight), methylprednisolone, and broad-spectrum
antibiotics (despite negative cultures). After consul-
ting neurology, the patient was diagnosed with DNS
given findings of fever, status epilepticus, and en-
cephalopathy without identifiable cause in the
setting of SMX. Over the next 4 years, no progression
occurred on a strict every-4-week IVIG (1 g/kg)
dosing schedule.
Three years after the initial episode of DNS, the
patient presented with anosmia and malaise 2 days
prior to scheduled IVIG treatment. Physical exam-
ination showed no progression of cutaneous disease
(Figs 2 and 3). Polymerase chain reaction testing of a
nasopharyngeal swab, however, confirmed SARS-
CoV-2 infection, precluding treatment at his regular
outpatient infusion center. Consequently, he was
admitted to the hospital to receive his scheduled
IVIG. During IVIG infusion, he developed altered
mental status, tonic-clonic movements, and fever
(up to 39.4 8C). Electroencephalography revealed
status epilepticus. He was transferred to the inten-
sive care unit, intubated, and treated with intrave-
nous antiepileptics and broad-spectrum antibiotics.
CSF analysis revealed mild pleocytosis (7 white
blood cells/L), mildly elevated protein (63 mg/
dL), and an opening pressure of 24 cm H2O. CSF
testing was negative for gram stain, Cryptococcus
antigen, and herpes simplex virus 1 and 2. Complete
blood count, comprehensive metabolic panel, uri-
nalysis, chest X-ray, blood cultures, and brain
computed tomography/magnetic resonance imag-
ing were unremarkable. Neurology was consulted
and could not identify underlying cause of the
precipitous neurologic decline; thus, recurrent
DNS was considered as the potential diagnosis.
The patient was treated with a 3-day course of
intravenous methylprednisolone and IVIG (3 g/kg
of ideal body weight).
Fig 1. Histology of lesional skin biopsy material revealing stromal hypercellularity in the upper
dermis (left; hematoxylin-eosin stain, original magnification 360) and increased interstitial
mucin deposition (right; colloidal iron stain, original magnification 360).
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DISCUSSION
We described 2 episodes of DNS in a patient with
SMX who presented with classic findings (fever,
confusion, and seizures) preceded by a flu-like
prodrome, with confirmed viral infection (influenza
A or SARS-CoV-2). Both episodes occurred despite
regular IVIG therapy. Possibly, antecedent infections
that elicit hyperinflammatory states may increase the
risk of developing DNS. Notably, recent infection or
vaccination also is speculated to underlie increased
risk of exacerbations in multiple sclerosis.20 By
limiting inflammation, low-dose glucocorticoids
could potentially mitigate the risk of DNS in SMX.
Indeed, some patients with SMX benefit from adjunct
glucocorticoids when IVIG maintenance therapy
fails to prevent progression of skin disease.
Importantly, other causes of neurologic decline
should be considered in the differential diagnosis
for DNS, such as the possibility of occult central
nervous system infection (despite equivocal CSF
studies) or neurologic manifestations of SARS-CoV-2.
Evaluation for infection in DNS often focuses on
ruling out neurotropic organisms (eg, herpes sim-
plex virus), but fails to test for many respiratory tract
or other systemic pathogens. To better understand
the association of DNS with infection, modern
techniques, such as BioFire, could be employed to
evaluate large panels of viruses and bacteria in SMX
patients acutely presenting with DNS.21 Cytokine
profiling of the serum and CSF of DNS patients




Fig 2. Scleromyxedema presenting as numerous 2 to 4-mmwaxy, perifollicular papules on the
upper extremities (left, right), face, trunk, and thighs. Some of the papules were arranged in a
linear configuration over the chest, a classic finding in scleromyxedema.
Fig 3. Scleromyxedema with numerous waxy 2 to 3-mm
papules on the brows and forehead. Induration of the
glabella, an early finding in progression to leonine facies,
can also be appreciated.
JAAD CASE REPORTS
VOLUME 18
Fritz et al 101
REFERENCES
1. Hoffmann JHO, Enk AH. Scleromyxedema. J Dtsch Dermatol
Ges. 2020;18(12):1449-1467. https://doi.org/10.1111/ddg.14319
2. Hummers LK. Scleromyxedema. Curr Opin Rheumatol. 2014;
26(6):658-662. https://doi.org/10.1097/BOR.0000000000000118
3. Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a
multicenter study of characteristics, comorbidities, course, and
therapy in 30 patients. J Am Acad Dermatol. 2013;69(1):66-72.
https://doi.org/10.1016/j.jaad.2013.01.007
4. Mahevas T, Arnulf B, Bouaziz JD, et al. Plasma cell-directed
therapies in monoclonal gammopathy-associated scleromyx-
edema. Blood. 2020;135(14):1101-1110. https://doi.org/10.
1182/blood.2019002300
5. Johkura K, Susuki K, Hasegawa O, Kuroiwa Y, Komatsumoto S.
Encephalopathy in scleromyxedema. Neurology. 1999;53(5):
1138-1140. https://doi.org/10.1212/wnl.53.5.1138
6. Bhoyrul B, Mughal AA, Paulus J, Salamat A, Howarth S. Does
dermatoneuro syndrome have a viral aetiology? Clin Exp
Dermatol. 2016;41(1):53-56. https://doi.org/10.1111/ced.12698
7. Marshall K, Klepeiss SA, Ioffreda MD, Helm KF. Scleromyxe-
dema presenting with neurologic symptoms: a case report
and review of the literature. Cutis. 2010;85(3):137-140.
8. River Y, Levy I, Gilead L, Orbach H, Almog Y. Fever, convulsions
and coma in scleromyxedema: a ‘‘dermato-neuro syndrome’’.
Neurology. 1996;46(6):1778-1779. https://doi.org/10.1212/
wnl.46.6.1778
9. Fleming KE, Virmani D, Sutton E, et al. Scleromyxedema and
the dermato-neuro syndrome: case report and review of the
literature. J Cutan Pathol. 2012;39(5):508-517. https://doi.org/
10.1111/j.1600-0560.2012.01882.x
10. Anguelova GV, Jellema K, Wagemakers S, Peters R. Two
patients with dermatoneuro syndrome after influenza A
infection. Eur J Neurol. 2021;28(8):e65-e66. https://doi.org/10.
1111/ene.14886
11. Devos T, Thiessen S, Cuyle PJ, Meersseman W, Delforge M.
Long-term follow-up in a patient with the dermato-neuro
syndrome treated with high-dose melphalan, thalidomide,
and intravenous immunoglobulins for more than 7 years. Ann
Hematol. 2014;93(11):1927-1928. https://doi.org/10.1007/
s00277-014-2065-5
12. Karaman B, Guler A, Ertam I, Celebisoy N. Dermato-neuro
syndrome associated with scleromyxedema. Indian J Dermatol
Venereol Leprol. 2015;81(5):519-521. https://doi.org/10.4103/
0378-6323.162344
13. Landais AF, Duchemin CM, Bourhis VM. Scleromyxedema
(papular mucinosis) with dermato-neuro syndrome: a rare,
potentially fatal complication. Presse Med. 2015;44(7-8):
850-851. https://doi.org/10.1016/j.lpm.2015.04.026
14. Larios JM, Ciuro J, Sam Varghese T, Lyons SE. Successful
treatment of dermato-neuro syndrome with plasmapheresis.
BMJ Case Rep. 2020;13(12):e237170. https://doi.org/10.
1136/bcr-2020-237170
15. Liu A, Suozzi K, Hwang DY, Moeller JJ, Lazova R, DiCapua D.
Dermatoneuro syndrome: a full recovery after a second
episode. Neurol Clin Pract. 2016;6(3):e27-e29. https://doi.org/
10.1212/CPJ.0000000000000221
16. Magira EE, Malouchou A, Karathanasi V, et al. Acute enceph-
alitic syndrome induced by scleromyxedema. Am J Med Sci.
2020;360(2):192-195. https://doi.org/10.1016/j.amjms.2020.
05.018
17. Rey JB, Luria RB. Treatment of scleromyxedema and the
dermatoneuro syndrome with intravenous immunoglobulin.
J Am Acad Dermatol. 2009;60(6):1037-1041. https://doi.org/
10.1016/j.jaad.2008.11.013
18. Shams SR, Goldstein DA, Kaufman JL, MacKelfresh J,
Flowers CR, Langston AA. Dermato-neuro syndrome in a
patient treated with autologous stem cell transplant for
scleromyxedema. Clin Lymphoma Myeloma Leuk. 2014;14(6):
e213-e215. https://doi.org/10.1016/j.clml.2014.06.018
19. Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema:
response to high-dose intravenous immunoglobulin (hdIVIg).
J Am Acad Dermatol. 2000;43(2):403-408. https://doi.org/10.
1067/mjd.2000.104001
20. Steelman AJ. Infection as an environmental trigger of multiple
sclerosis disease exacerbation. Front Immunol. 2015;6:520.
https://doi.org/10.3389/fimmu.2015.00520
21. Creager HM, Cabrera B, Schnaubelt A, et al. Clinical evaluation
of the BioFire Respiratory Panel 2.1 and detection of




102 Fritz et al
